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Abstract
Platelets represent an important link between inflammation and thrombosis and play an important role in all stages of 
atherosclerotic lesion formation. Increased platelet activity and their tendency to clot formation favour the incidence of 
thrombotic complications, such as unstable angina pectoris (UA), myocardial infarction (MI) and sudden cardiac death, 
in the course of coronary artery disease (CAD). Mean platelet volume (MPV) reflects the average size of platelets and, 
under normal circumstances, ranges between 7.5 fL to 10.5 fL. Platelet-large cell ratio (P-LCR) is defined as the percen-
tage of platelets that exceed the normal value of platelet volume of 12 fL in the total platelet count. Platelet size has 
been shown to reflect platelet activity; therefore MPV and P-LCR are a simple and easy method of indirect assessment 
of platelet stimulation. In general population, higher MPV values are associated with increased risk of CAD. Higher 
MPV and P-LCR values are observed in CAD patients compared to patients without coronary atherosclerosis. In acute 
coronary syndromes (ACS) the MPV value is higher in patients with myocardial infarction than in patients with unstable 
CAD. In cases of stable CAD, elevated MPV correlates with the severity of coronary artery involvement and is a predic-
tive factor of ACS. In patients with acute MI high MPV value has been reported to have impact on the no-reperfusion 
phenomenon following a percutaneous coronary intervention (PCI). Therefore, MPV and P-LCR indices, combined with 
other prognostic parameters, may be an important element of various scoring systems used in long-term prognosis in 
both stable CAD and ACS.
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Introduction
Thrombotic complications of atherosclerosis are, inter alia, 
connected with platelet function, including their activation 
and the ability to aggregate [1–2]. Mean platelet volume 
(MPV) reflects the average size of platelets (ranges from 
7.5 fL to 10.5 fL), while the platelet-large cell ratio (P-LCR) 
reflects the proportion of platelets greater than 12 fL (the 
norm for P-LCR is < 30% in the total platelet count).
Larger platelets are usually relatively young and contain 
more intracellular granules. They have, therefore, greater 
thrombogenic potential [3–4]. Platelets size is determined by 
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the rate of platelet turnover [5]. At the developmental stage 
of precursor cells (megakaryocytes) the activity of cytokines 
(especially interleukin 3 and interleukin 6) plays a signifi-
cant role in the regulation of platelet pool and leads to the 
production of larger platelets that are more reactive [6–8].
Increased MPV value is associated, among others, with 
hypertension [9], diabetes mellitus [10–11], renal failure 
[12] and atrial fibrillation [13]. Higher MPV values were 
also observed in the elderly [14], obese patients [15] and 
smokers [4, 16–17]. P-LCR is not routinely reported in 
a complete blood count. However, there exist some data 
suggesting its prognostic value similar to that of MPV.
Because platelets form an important link between 
inflammation and thrombotic complications in atheroscle-
rosis [18], this paper attempts to review an up-to-date 
outlook for the assessment of platelet indices in patients 
with coronary artery disease (CAD).
The role of MPV and P-LCR  
in stable coronary artery disease  
and acute coronary syndromes
In patients with stable CAD, higher MPV and P-LCR values 
are observed in comparison with healthy persons [1], 
whereas in ACS the indices are higher in cases of myo-
cardial infarction than in unstable CAD [4]. For example, 
Khode et al. have proven that MPV is significantly higher 
in patients with myocardial infarction (9.65 ± 0.96 fL) than 
in stable CAD patients (9.37 ± 0.88 fL) and lowest in the 
control group (9.21 ± 0.58 fL) [19]. Additionally, Pol et al. 
have demonstrated greater MPV values in acute coronary 
syndrome (ACS) patients compared with non-ACS patients 
(11.44 ± 1.23 fL versus 9.91 ± 1.27 fL) [20]. Thus, the rise 
in MPV and P-LCR values may be considered a hallmark of 
plaque thrombosis.
MPV and the complexity  
of coronary artery disease
Sani Namik Murat et al., in order to assess the CAD severity 
and complexity, have used the Gensini and SYNTAX scores 
[21]. Patients were divided into two groups according to the 
MPV value — one with low MPV (8.3 ± 0.9 fL) and second 
with high MPV (10.8 ± 0.4 fL). Both angiographic Gensini 
and SYNTAX scores were higher in patients with high MPV 
value compared to patients in the low MPV group (9.5 ± 
± 4.4 versus 7.9 ± 4.0 on the Gensini score and 16.1 ± 8.4 
versus 13.9 ± 9.0 on the SYNTAX score, respectively). In 
multifactorial analysis MPV was found to be an independent 
factor correlating with the degree of coronary artery athe-
rosclerosis. Another study also confirmed the relationship 
between MPV and atherosclerosis’ complexity according 
to the Gensini and SYNTAX scores [22]. Using the Gensini 
score, patients have been divided into three subgroups: 
patients with no coronary lesions (Gensini score 0), with 
minimal coronary lesions (Gensini score 1–9) and with 
significant coronary atherosclerosis (Gensini score ≥ 20). 
Additionally, the SYNTAX score has been used to divide 
patients into four subgroups: control group (SYNTAX score 
= 0), low SYNTAX group (SYNTAX score 1–22), medium SYN-
TAX group (SYNTAX score 23–32) and high SYNTAX group 
(SYNTAX score > 33). Using both the Gensini and SYNTAX 
scores evaluations, statistically significant differences in 
MPV values were found in all analysed subgroups. Spear-
man analysis revealed a positive correlation between MPV 
and the Gensini score (p < 0.001, r = 0.290).
Coronary ar tery calcification can be quantified 
using the coronary calcium score from multi-detected 
row computed tomography. It is believed that coronary 
calcification detected by using computed tomography 
scanning is a pathognomonic feature of atherosclerosis 
[23]. In this case, the Calcium Score (CS) indicates the 
amount of coronary artery calcification and is a surro-
gate marker that reflects the coronary atherosclerotic 
plaque burden [24]. Lesions that remain undetected 
during contrast angiography (because of plaque posi-
tive remodelling in the arterial wall) can be visualized 
through computed tomography before they protrude into 
the lumen of the vessel. For that reason, quantitative 
assessment of calcification reflects the advancement of 
the atherosclerotic process better than contrast angio-
graphy, which cannot detect the early stages of plaque 
formation [25]. Therefore, it is important to discuss the 
relation between MPV and the Calcium Score. In the 
Dong Hyuk et al. analysis, which encompassed over 
2000 general population patients, it has been proven 
that the MPV was significantly higher in patients with 
a positive CS than in the control group (CS = 0) [26]. 
Multivariate analyses showed that MPV was positively 
associated with coronary calcification (odds ratio [OR], 
1.61; 95% confidence interval [CI] 1.02–2.55).
To conclude, MPV correlates with the complexity and 
severity of CAD according to the Gensini and SYNTAX sco-
res, as well as with the total plaque burden assessed by 
the Calcium Score.
The prognostic value of MPV  
in patients with CAD
Recently, MPV emerged as a cardiovascular risk factor in 
general population as well as in patients with CAD and 
ACS. For instance, in an Austrian population of 200,000 
people, it has been shown that MPV over 11.01 fL was an 
independent risk factor for cardiovascular mortality [2]. 
In long-term observation, all-causes mortality risk was 
1.5-times higher and coronary disease-related mortality 
was 1.8-times higher in individuals in the highest quintile 
of MPV value. [27].
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In a multivariate analysis performed by Ozkan et al., 
MPV has been documented to be an independent myocar-
dial infarction risk factor in men under the age of 44 and 
in women under the age of 55 [28]. Also, some other 
publications underline the prognostic significance of MPV 
in CAD patients [29–31].
For example, Alon Eisen et al. have demonstrated that 
in the analysed population of over 7500 CAD patients 
undergoing PCI, MPV was higher in individuals over the 
age of 75, in women, in cases of diabetes mellitus and 
in patients with ACS than it was in stable CAD patients 
[29]. In multivariate analysis, MPV remained a significant 
risk factor for mortality and the incidence of composite 
endpoints (death, myocardial infarct or the necessity for 
revascularization). In addition, MPV value at admission was 
a significant prognostic factor in cases of both planned PCI 
and emergency PCI.
MPV is also a substantial prognostic factor in patients 
with ST-elevation myocardial infarction. Akgul et al. have di-
vided the analysed cohort into 2 groups depending on MPV: 
Group 1 with MPV ≤ 8.9 and group 2 with MPV > 8.9 [30]. 
The group with higher MPV showed greater in-hospital mor-
tality than group 1. In 6-month observation, the percentage 
of deaths in group 2 was greater compared to the group with 
lower MPV value. Age, MPV over 8.9 fL, anaemia at admis-
sion, low left ventricle ejection fraction and unsuccessful 
revascularization proved to be independent mortality risk 
factors in 6-month observation. MPV value of over 8.9 fL 
predicted all-causes death in 6-month observation with 
high sensitivity (73.2%) and specificity (74%).
Also Rechciński et al. have demonstrated that MPV 
and P-LCR remain related to greater long-term mortality in 
patients with STEMI undergoing PCI [31]. In individuals with 
MPV ≥ 11.7 fL long-term mortality was nearly three times 
higher in comparison with patients with MPV < 11.7 fL. 
In cases of P-LCR values equal or over 38.1% mortality 
was also significantly higher compared to individuals with 
lower values.
Mean platelet volume  
and tissue reperfusion
In a large number of patients with acute myocardial in-
farction, despite restoring the patency of the infarct-related 
artery, there is no myocardial reperfusion [32–36]. The 
occurrence of such phenomenon is associated with worse 
long-term prognosis and higher risk of recurrent myocardial 
infarction.
The term ‘no-reflow’ was introduced by Kloneli et al. in 
1974 [37]. Although primarily it was used to describe lack 
of reperfusion in animal models consisting of a temporary 
ligation of a coronary artery, further observations of this 
phenomenon in the aspect of PCI procedures resulted in the 
distinction between the ‘no-reflow’ and ‘no-reperfusion’ [38].
Among numerous factors responsible for the lack of 
tissue reperfusion after reperfusion therapy in patients 
with acute myocardial infarction, the following can be li-
sted: leucocytosis, C-reactive protein (CRP) concentration, 
endothelin, von Willebrand factor (vWF) and fibrinogen 
concentration, MPV and in general, blood flow properties 
(blood fluidity) [39–41].
Maden et al. have reported reperfusion disturbances in 
about 40% of acute myocardial infarction patients treated 
with percutaneous coronary intervention (PCI) [42]. Indivi-
duals with impaired tissue blood flow were characterized 
by higher MPV values compared to patients with effective 
myocardial reperfusion (9.8 ± 1.3 versus 8.6 ± 1.0 fL, 
p < 0.001). Using regression analysis, MPV was shown to 
be independently related to impaired myocardial blood flow. 
The MPV cut-off value that best predicted compromised 
reperfusion has been established at 9.05 fL with sensitivity 
of 74% and specificity of 73%.
Also some other observations point out the relationship 
between tissue reperfusion and MPV value at admission 
[43–46]. In the analysis performed by Estévez-Loureiro et 
al., it has been shown that MPV independently predicts 
infarct-related artery patency before reperfusion as well as 
30-day mortality in patients with STEMI undergoing PCI [47].
Conclusion
In general population, high value of MPV has negative 
prognostic impact. In stable CAD patients, compared with 
non-CAD individuals, MPV correlates with the severity of 
coronary artery disease. In myocardial infarction, high 
MPV value is linked with the no-reperfusion phenomenon 
and is related to the increase of in-hospital and long-term 
mortality. Thus, platelet indices such as MPV and P-LCR 
in association with other predictive parameters may be 
utilized as important elements of various risk scores to 
assess outcome in both coronary artery disease and acute 
coronary syndromes.
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Streszczenie
Płytki krwi są ważnym ogniwem łączącym zapalenie i zakrzepicę oraz odgrywają istotną rolę na wszystkich etapach po-
wstawania zmian miażdżycowych. Zwiększona aktywność płytek krwi powodująca nasiloną krzepliwość krwi przyczynia 
się do większej liczby powikłań zakrzepowych, takich jak niestabilna dławica piersiowa (UA), zawał serca (MI) i nagły 
zgon sercowy w przebiegi choroby wieńcowej (CAD). Średnia objętość płytki krwi (MPV) odpowiada przeciętnej wielkości 
płytek i w normalnych warunkach mieści się w zakresie od 7,5 fl do 10,5 fl. Wskaźnik płytkowy dużych komórek (P-LCR) 
jest definiowany jako odsetek płytek krwi przekraczających zakres prawidłowej objętości płytek wynoszący powyżej 
12 fl. Wykazano, że wielkość płytek odzwierciedla ich aktywność, dlatego oznaczenie MPV i P-LCR to proste i łatwe meto-
dy pośredniej oceny stopnia stymulacji płytek krwi. W populacji ogólnej wyższe wartości MPV wiążą się ze zwiększonym 
ryzykiem CAD. U chorych z CAD obserwuje się wyższe wartości MPV i P-LCR niż u osób bez zmian miażdżycowych tętnic 
wieńcowych. W grupie chorych z ostrymi zespołami wieńcowymi (ACS) wartość MPV jest wyższa u osób z rozpoznaniem 
zawału serca niż u osób z niestabilną CAD. W przypadku stabilnej CAD wielkość MPV koreluje z ciężkością zmian w tęt-
nicach wieńcowych i jest czynnikiem predykcyjnym ACS. Opisywano wpływ wysokich wartości MPV u chorych z ostrym MI 
na występowanie zjawiska braku reperfuzji po przezskórnej interwencji wieńcowej (PCI). Dlatego wskaźniki MPV i P-LCR 
w połączeniu z innymi prognostycznymi parametrami mogą być ważnym elementem różnych systemów oceny ryzyka 
w perspektywie długookresowej zarówno w stabilnej CAD, jak i ACS.
Słowa kluczowe: MPV, P-LCR, choroba wieńcowa, zawał serca
(Folia Cardiologica 2015; 10, 6: 418–422)
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